Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

Antiretroviral therapy to treat and prevent HIV/AIDS in resource-poor settings

Nature Medicine volume 8, pages 651–654 (2002)Cite this article

Prior to the XIIIth World AIDS Conference in Durban, debate raged in the community over the practicalities, cost and ethics of delivering antiretroviral drugs to the developing world. Two years on, that discussion is history. Political and financial forces will now deliver these drugs to such nations. How then can we expect their arrival to alter the HIV landscape?

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Mathematical model simulations of the potential epidemiological impact of the use of antiviral treatments in a generalized HIV epidemic where ARVs are introduced 30 years after the start of the epidemic.

References

  1. UNAIDS & WHO. AIDS Epidemic Update: December 2001. (Joint United Nations Programme on HIV/AIDS (UNAIDS), Geneva, Switzerland, 2001).

  2. Communicable Disease Surveillance Centre. AIDS and HIV infection in the United Kingdom. in CDR Weekly (http://www.hpa.org.uk/infections/default.htm) (2002).

  3. UNGASS. United Nations General Assembly Special Session S-26/2 Declaration of Commitment on HIV/AIDS (United Nations, 2001).

  4. Schwartlander, B. et al. Resource needs for HIV/AIDS. Science 292, 2434–2436 (2001).

    Article  CAS  Google Scholar 

  5. Ramsay, S. Global Fund makes historic first round of payments. Lancet 359, 1581–1582 (2002).

    Article  Google Scholar 

  6. France, T., Ooms, G. & Rivers, B. The Global Fund: Which countries owe how much? (Health & Development Networks (HDN), (http://www.hdnet.org) (2002).

  7. Yarney, G. & Rankin, W.W. AIDS and global justice: Resources from the global AIDS fund must reach the poorest. BMJ 324, 181–182 (2002).

    Article  Google Scholar 

  8. Berwick, D. We all have AIDS: Case for reducing the cost of HIV drugs to zero. BMJ 324, 214–216 (2002).

    Article  Google Scholar 

  9. Farmer, P. & Kim, J. Community-based approaches to the control of multidrug resistance tuberculosis: introducing DOTS-plus. BMJ 317, 671–674 (1998).

    Article  CAS  Google Scholar 

  10. Harries, A., Nyangulu, D., Hargreaves, N., Kaluwa, O. & Salaniponi, F. Preventing antiviral anarchy in sub-Saharan Africa. Lancet 358, 410–414 (2001).

    Article  CAS  Google Scholar 

  11. Churchyard, G.J., Corbett, E.L., Kleinschmidt, I., Mulder, D. & De Cock, K.M. Drug-resistant tuberculosis in South African gold miners: Incidence and associated factors. Int. J. Tuberc. Lung Dis. 4, 433–440 (2000).

    CAS  PubMed  Google Scholar 

  12. Kenyon, T.A. et al. Low levels of drug resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus co-epidemics in Botswana. Int. J. Tuberc. Lung Dis. 3, 4–11 (1999).

    CAS  PubMed  Google Scholar 

  13. Warndorff, D.K. et al. Trends in antituberculosis drug resistance in Karonga District, Malawi, 1986–1998. Int. J. Tuberc. Lung Dis. 4, 752–757 (2000).

    CAS  PubMed  Google Scholar 

  14. Kuaban, C., Bercion, R., Jifon, G., Cunin, P. & Blackett, K.N. Acquired anti-tuberculosis drug resistance in Yaounde, Cameroon. Int. J. Tuberc. Lung Dis. 4, 427–432 (2000).

    CAS  PubMed  Google Scholar 

  15. Adje, C. et al. High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Cote d'Ivoire. J. Acquir. Immune Defic. Syndr. 26, 501–506 (2001).

    Article  CAS  Google Scholar 

  16. Vergne, L. et al. Resistance to antiretroviral treatment in Gabon: Need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries. J. Acquir. Immune Defic. Syndr. 29, 165–168 (2002).

    Article  CAS  Google Scholar 

  17. Hogg, R.S. et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after one year of follow-up. AIDS 16, 1051–1058 (2002).

    Article  Google Scholar 

  18. WHO. Scaling up antiretroviral therapy in resource limited settings: Guidelines for a public health approach. 1–115 (http://www.who.int/HIV_AIDS/HIV_AIDS_Care/ ARV_Draft_April_2002.pdf) (2002).

  19. Yerly, S. et al. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 354, 729–733 (1999).

    Article  CAS  Google Scholar 

  20. Boden, D. et al. HIV-1 drug resistance in newly infected individuals. JAMA 282, 1135–1141 (1999).

    Article  CAS  Google Scholar 

  21. Gray, R.H. et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 357, 1149–1153 (2001).

    Article  CAS  Google Scholar 

  22. Anderson, R.M., Gupta, S. & May, R.M. Potential of community-wide chemotherapy or immunotherapy to control the spread of HIV-1. Nature 350, 356–359 (1991).

    Article  CAS  Google Scholar 

  23. Ekstrand, M.L., Stall, R.D., Paul, J.P., Osmond, D.H. & Coates, T.J. Gay men report high rates of unprotected anal sex with partners of unknown or discordant HIV status. AIDS 13, 1525–1533 (1999).

    Article  CAS  Google Scholar 

  24. Dodds, J.P., Nardone, A., Mercey, D.E. & Johnson, A.M. Increase in high risk sexual behavior among homosexual men, London 1996–8: Cross sectional, questionnaire study. BMJ 320, 1510–1511 (2000).

    Article  CAS  Google Scholar 

  25. Van de Ven, P., Prestage, G., Crawford, J., Grulich, A. & Kippax, S. Sexual risk behavior increases and is associated with HIV optimism among HIV-negative and HIV-positive gay men in Sydney over the 4 year period to February 2000. AIDS 14, 2951–2953 (2000).

    Article  CAS  Google Scholar 

  26. Katz, M.H. et al. Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco. Am. J. Public Health 92, 388–394 (2002).

    Article  Google Scholar 

  27. Sweat, M. et al. Cost-effectiveness of voluntary HIV-1 counseling and testing in reducing sexual transmission of HIV-1 in Kenya and Tanzania. Lancet 356, 113–121 (2000).

    Article  CAS  Google Scholar 

  28. World Bank. Confronting AIDS: Public Priorities in a Global Epidemic (Oxford University Press, Oxford) (1999).

Download references

Author information

Authors and Affiliations

  1. Department of Infectious Disease Epidemiology Faculty of Medicine Imperial College of Science, Technology and Medicine London University, UK

    Geoff P. Garnett, Lucy Bartley, Nicholas C. Grassly & Roy M. Anderson

Authors
  1. Geoff P. Garnett
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lucy Bartley
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nicholas C. Grassly
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Roy M. Anderson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Garnett, G., Bartley, L., Grassly, N. et al. Antiretroviral therapy to treat and prevent HIV/AIDS in resource-poor settings. Nat Med 8, 651–654 (2002). https://doi.org/10.1038/nm0702-651

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0702-651

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing